Key Insights• According to the research report, "Brazil EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Brazil EPA & DHA Market is anticipated to add to more than USD 29.01 Million by 2026-31.The Brazilian EPA & DHA market is steadily expanding as the country faces a growing burden of cardiovascular and chronic disease driven by rapid population aging, rising obesity, and increasing consumer adoption of dietary supplements. According to IBGE, Brazil's population reached 213.4 million in 2025, while people aged 60 and older already accounted for 15.6% of the population in 2023, overtaking the 15–24 age group for the first time, with IBGE projecting this share to reach around 28% by 2046. According to the Brazilian Society of Cardiology's (SBC) Cardiômetro, cardiovascular disease caused 417,550 deaths in Brazil in 2024, and 318,945 deaths had been recorded in 2026 through mid-October, equivalent to one death roughly every 72 seconds. The growing clinical burden is placing additional pressure on Brazil's Unified Health System (SUS), private health plans, and consumer health sector to strengthen access to EPA and DHA through supplements, fortified foods, infant nutrition, and clinical nutrition.• Brazil's EPA & DHA market is characterized by a large and dynamic consumer health ecosystem comprising domestic supplement brands, multinational nutrition companies, pharmacy chains, sports nutrition retailers, and one of the world's largest pet care industries. Pharmacy chains such as RD Saúde (Drogasil and Droga Raia), Pague Menos, and DPSP function as the primary distribution channels for omega-3 supplements, alongside e-commerce platforms such as Mercado Livre and Amazon Brasil. Domestic brands including Vitafor, Essential Nutrition, Catarinense Nutrição, and Vitgold offer fish oil and krill oil products alongside multinational players.

According to the Brazilian Association of the Food Industry for Special Purposes (ABIAD), apparent consumption of food supplements and vitamin supplements grew 5.8% in the first nine months of 2024 compared with the same period of 2023, and six in 10 Brazilians already use these products to complement their diet. Aker BioMarine has also cited South America, alongside China and Europe, as a key source of growth for its krill-based Human Health Ingredients business in 2025.• Regulatory oversight for EPA and DHA products is administered by the Brazilian Health Regulatory Agency (ANVISA) through a dedicated framework for dietary supplements established under RDC No. 243/2018 and its associated Normative Instruction listing permitted ingredients, limits, and authorized claims. ANVISA's updated food regularization rules, in force since September 2024, require supplements to be notified to the agency and to display a unique notification number and the statement "Alimento notificado na Anvisa," with full compliance required by September 2025. Prescription omega-3 medicines require registration as drugs, while pet food is regulated by the Ministry of Agriculture and Livestock (MAPA). The Brazilian EPA & DHA market is largely supplied through imported refined fish oil, krill oil, and algal oil from Peru, Chile, Norway, and other origins, with domestic encapsulation capacity serving local brands.Market Outlook• A defining characteristic of Brazil's EPA & DHA market is the progressive modernization and formalization of the dietary supplement sector under ANVISA's specific supplement framework. The 2018 regulation created clear rules on permitted EPA and DHA sources, minimum and maximum levels, and authorized claims, including an approved claim linking EPA and DHA consumption to the maintenance of healthy triglyceride levels.

The new notification requirement introduced in September 2024 is strengthening traceability and enabling consumers to verify product regularization, encouraging consolidation toward established brands with consistent quality. Simultaneously, Brazilian consumers are shifting toward higher-concentration omega-3 formats, krill oil, and algal DHA, while sports nutrition retailers and nutritionists are promoting omega-3 for recovery, cognitive function, and healthy aging.• The market also reflects Brazil's growing emphasis on chronic disease prevention and healthy aging. Public health initiatives within SUS and private health plans promoting cardiovascular risk management are increasing awareness of lipid control and nutrition, while ANVISA's front-of-pack nutrition labelling system, fully phased in by October 2025, is encouraging food manufacturers to develop products with improved nutritional profiles, creating opportunities for omega-3-enriched foods. In infant nutrition, IBGE's Civil Registry Statistics show that Brazil recorded approximately 2.38 million births in 2024, a 5.8% decline from 2023 and the sixth consecutive annual decrease, which is constraining formula volumes but encouraging manufacturers to focus on premium DHA-fortified formulations.Market DynamicsDriver: Rising cardiovascular disease burden and rapid demographic aging supported by high supplement adoptionBrazil's EPA & DHA market is primarily driven by the growing prevalence of cardiovascular and metabolic conditions associated with demographic aging and lifestyle-related risk factors. Cardiovascular disease remains the leading cause of death in Brazil, with the SBC Cardiômetro recording 417,550 deaths in 2024 and 318,945 deaths in 2026 through October 16, approximately 1,194 deaths per day. The population aged 60 and older represented 15.6% of the total in 2023 and is projected to rise to around 28% by 2046 and 37.8% by 2070, according to IBGE.

Supplement use is widespread, with ABIAD reporting that six in 10 Brazilians use food supplements and that apparent consumption grew 5.8% in the first nine months of 2024. Omega-3 is among the most recommended supplements by cardiologists, nutritionists, and pharmacists for cardiovascular, cognitive, and joint health. As public and private healthcare providers continue promoting cardiovascular prevention, pharmacies and retailers are witnessing growing demand for high-quality EPA and DHA products.Challenge: Currency volatility, import dependence, and regulatory compliance costsOne of the principal challenges facing Brazil's EPA & DHA market is the country's dependence on imported refined marine oils and the exposure of brands to currency fluctuations. Most refined fish oil, krill oil, and algal oil used in Brazilian supplements is imported, making product costs highly sensitive to movements in the real against the U.S. dollar and to global raw material prices. Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early in both 2025 and 2026 after reaching its catch trigger level. Additionally, compliance with ANVISA's supplement notification and labelling requirements, with full conformity required by September 2025, has increased administrative costs for smaller brands, and the market continues to face challenges from irregular products sold online that do not meet regulatory standards.

Together, these factors contribute to pricing pressure and limit access to premium omega-3 formats among lower-income consumers.Trend: Premiumization through krill, algal, and high-concentration omega-3 alongside pet nutrition growthBrazil is experiencing a significant shift toward premium omega-3 formats supported by consumer interest in purity, absorption, and sustainability. Krill oil products from domestic brands such as Essential Nutrition and Vitgold are widely available in leading pharmacy chains, while algal DHA is gaining traction in vegan and prenatal ranges. High-concentration triglyceride fish oils and small-capsule formats are increasingly positioned for consumers seeking higher EPA and DHA doses per serving. Simultaneously, the pet sector is emerging as a major demand pocket. Brazil is the world's third-largest pet market after the U.S. and China, with revenue exceeding BRL 77 billion in 2024, up approximately 12% from 2023, and a pet population of more than 164 million animals according to Abinpet. Premium pet foods and supplements increasingly incorporate fish oil for skin, coat, joint, and cognitive health.

The growing emphasis on e-commerce, subscription models, and digital health platforms is expected to further strengthen category penetration.Policies• ANVISA Dietary Supplement Framework (RDC No. 243/2018): Dietary supplements containing EPA and DHA are regulated under RDC No. 243/2018, which defines composition, quality, safety, and labelling requirements. ANVISA's Normative Instruction establishes the list of permitted ingredients, minimum and maximum levels, and authorized claims, including a claim relating EPA and DHA consumption to the maintenance of healthy triglyceride levels when combined with a balanced diet and healthy lifestyle.• Food Regularization and Notification Requirements: ANVISA's updated food regularization rules, in force since September 2024, require supplements to be notified to the agency before marketing, with labels displaying a unique notification number and the statement "Alimento notificado na Anvisa." Manufacturers were required to be in full compliance by September 2025, improving traceability and market surveillance.• Front-of-Pack Nutrition Labelling: ANVISA's nutrition labelling rules under RDC No. 429/2020 and IN No. 75/2020 require magnifying-glass front-of-pack warnings for high levels of added sugars, saturated fats, and sodium, and a standardized nutrition facts table. The phased implementation was completed by October 2025, influencing the formulation and positioning of omega-3-enriched foods and beverages.• Infant Formula Regulation: Infant formulas and follow-on formulas are regulated under specific ANVISA resolutions defining compositional requirements, in which DHA and ARA are permitted optional ingredients subject to defined limits. The Brazilian Code for the Marketing of Foods for Infants and Young Children (NBCAL) restricts the promotion of infant formula, shaping marketing strategies for DHA-fortified products.• Medicine Registration and Pet Food Regulation: Prescription omega-3 medicines must be registered with ANVISA as drugs, including evidence of quality, safety, and efficacy. Pet foods and pet supplements containing fish oil are regulated by MAPA, which oversees product registration, labelling, and manufacturing establishment licensing.Segment AnalysisBrazil EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Brazil, particularly in infant formula, prenatal supplements, and children's nutrition products. DHA-focused prenatal supplements are widely recommended by obstetricians, and algal DHA is gaining share in vegan and prenatal ranges.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Brazil, driven by increasing demand for high-EPA concentrates for cardiovascular health, mood support, and sports recovery, supported by recommendations from cardiologists, nutritionists, and sports nutrition professionals.Brazil EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Brazil due to its cost-effectiveness and broad consumer familiarity.

Refined fish oil is primarily imported from Peru, Chile, and Europe and encapsulated domestically by local brands and contract manufacturers.• Algae Oil maintains a growing position within Brazil, particularly in infant formula, vegan supplements, and prenatal products, supplied by multinational algal oil producers.• Krill Oil is a premium source category with strong visibility in Brazilian pharmacy chains through brands such as Essential Nutrition and Vitgold. Aker BioMarine cited South America as a key contributor to the 16% year-over-year growth of its Human Health Ingredients segment in the first quarter of 2025.• Other Marine Sources hold a niche position in the Brazilian market, including cod liver oil, salmon oil, and sardine oil, primarily used in traditional supplements and pet nutrition.Brazil EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Brazil, supported by high supplement adoption, with six in 10 Brazilians using food supplements according to ABIAD. Omega-3 supplements are sold through pharmacies, sports nutrition stores, supermarkets, and e-commerce.• Pharmaceuticals represent an important application segment, including prescription omega-3 medicines for hypertriglyceridemia distributed through private pharmacies, with limited public reimbursement through SUS.• Infant Formula represents a strategically important application segment, with DHA widely included in infant formulas and follow-on formulas. Approximately 2.38 million births were recorded in 2024, sustaining sizeable formula demand despite a 5.8% decline.• Food & Beverages encompasses omega-3-enriched milk, eggs, bread, and functional beverages, with reformulation encouraged by ANVISA's front-of-pack labelling system.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in public and private hospitals for critically ill, surgical, and oncology patients.• Pet Nutrition represents the fastest-growing application segment in Brazil, supported by the world's third-largest pet market, with revenue exceeding BRL 77 billion in 2024 and more than 164 million pets, according to Abinpet. Fish oil is widely incorporated into premium pet foods and supplements.Major EPA & DHA Manufacturers Operating in Brazil• Vitafor, Essential Nutrition, Catarinense Nutrição, Vitgold, Nestlé, Danone, Abbott, Herbalife, dsm-firmenich, KD Pharma Group, and Aker BioMarine are leading players in the Brazilian EPA & DHA market, offering finished supplements, DHA-fortified infant formula, refined fish oil ingredients, algal oil, and krill oil. Their strong presence, broad pharmacy distribution, nutritionist and physician engagement, and established relationships with retailers have driven adoption across the Brazilian market.• The market is also supported by contract manufacturers, ingredient distributors, and pet food producers that provide formulation, encapsulation, and import support.

With a large consumer base, high supplement adoption, and one of the world's largest pet markets, Brazil remains the leading omega-3 market in Latin America.Brazil EPA & DHA Supply and Pricing Economics• EPA and DHA products in Brazil represent value-added nutritional products whose pricing depends on source, concentration, brand positioning, and import costs. Pricing varies considerably between standard fish oil, high-concentration oils, krill oil, and algal oil.• Retail prices are highly sensitive to exchange rate movements, import duties, and logistics costs. Refined fish oil prices normalized by late 2024 after the El Niño-related disruption, but the reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on raw material prices.• Supplements are paid out-of-pocket, with pharmacy chains offering private-label and promotional pricing to expand access. Prescription omega-3 medicines are largely paid privately, as SUS coverage is limited.• Pet nutrition products incorporating omega-3 command premium price points through pet shops, veterinary clinics, and e-commerce platforms.Market Outlook by Consumer Health Spending and Supply Infrastructure• Brazil's EPA & DHA market growth is strongly linked to consumer health spending, demographic aging, and the strength of the pharmacy and e-commerce channels, although currency volatility and import dependence remain significant factors influencing pricing and adoption.• Private consumer spending drives the supplement and pet nutrition segments, while pharmacy chains and digital platforms continue to expand omega-3 visibility through private labels, loyalty programs, and pharmacist guidance.• The future growth opportunity for EPA and DHA in Brazil depends on strengthening regulatory compliance under ANVISA's notification framework, expanding consumer education on the benefits of omega-3, developing omega-3-fortified foods aligned with front-of-pack labelling, and capturing demand from the rapidly growing pet sector. Greater integration of e-commerce, nutritionist recommendations, and premium krill and algal formats will likely become key strategies for sustaining long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.